3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
28
Phase 1
14
Phase 1/2
7
Phase 3
6
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Esophageal Squamous Cell Carcinoma
8
Esophageal Neoplasms
7
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Nasopharyngeal Carcinoma
6
Lung Neoplasms
6
Head and Neck Neoplasms
5
Gallbladder Neoplasms
5
Cholangiocarcinoma
5
Pancreatic Neoplasms
4
Mesothelioma
4
Breast Neoplasms
4
Biliary Tract Neoplasms
4
Stomach Neoplasms
3
Oropharyngeal Neoplasms
3
Neoplasm Metastasis
3
Carcinoma
3
Urinary Bladder Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Bile Duct Neoplasms
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Testicular Neoplasms
1
Interventions
Pemetrexed
1
Cisplatin
1
Carboplatin
1
ADI PEG20
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Mesothelioma, Malignant
×
Cisplatin
×
Clear all
NCT02709512
2023-10-04
ATOMIC
Polaris Group
Phase 2/3
Completed
249 enrolled
17 charts